Q4 2022 13F Holders as of 31 Dec 2022
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
27,795,576
-
Number of holders
-
69
-
Total 13F shares, excl. options
-
25,462,485
-
Shares change
-
-1,612,879
-
Total reported value, excl. options
-
$17,969,636
-
Value change
-
-$2,260,786
-
Put/Call ratio
-
2387%
-
Number of buys
-
20
-
Number of sells
-
33
-
Price
-
$0.7060
Institutional Holders of Accelerate Diagnostics, Inc. - Common Stock, par value $0.001 per share (AXDX) as of Q4 2022
As of 31 Dec 2022 Accelerate Diagnostics, Inc. - Common Stock, par value $0.001 per share (AXDX) had 69 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 25,462,485 shares of stock of the company.
Largest 10 holders included GRIFFIN ASSET MANAGEMENT, INC., VANGUARD GROUP INC, Birchview Capital, LP, ORACLE INVESTMENT MANAGEMENT INC, JPMORGAN CHASE & CO, Alyeska Investment Group, L.P., Cannell & Co., MILLENNIUM MANAGEMENT LLC, BlackRock Inc., and GSA CAPITAL PARTNERS LLP.
This table shows 69 institutional shareholders of the security as of 31 Dec 2022.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.